Back to News
Market Impact: 0.4
Surrozen's SZN-8141 IND Cleared By FDA For Diabetic Macular Edema
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Surrozen said the FDA cleared its IND application for SZN-8141, allowing the company to begin clinical development of the candidate for diabetic macular edema. The clearance is a meaningful regulatory milestone that advances Surrozen's ophthalmology pipeline, though clinical efficacy and safety results remain key future risks.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
SRZN0.80
More News
- Surrozen receives FDA clearance for SZN-8141 IND application
- Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
- Mark Ruffalo says Paramount’s $111 billion Warner Bros. deal ‘Will stifle creativity, weaken free speech, and cost people their jobs’
- States, cities sue U.S. agencies over weaker vehicle fuel economy rules
- Anthropic warns government attitudes may hurt customer ties, IPO prospectus shows: Reuters
- Paramount and Warner Bros Discovery to become Skydance